Effects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary review
- Design
- Narrative review · None outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: a review scoped to people using GLP-1 RAs for type 2 diabetes and obesity who seek aesthetic surgery, conditions the target group does not have; no participant data are reported.
- Could weight loss explain it?
- PossiblyPossibly: the authors say direct drug effects often cannot be separated from the consequences of weight loss or baseline metabolic risk, and they judge that facial volume loss more plausibly reflects rapid weight loss than a drug-specific effect; no analysis separates the two.
- Study tier
- Not ratedNOT_RATED: a narrative review with no new primary outcome data and no pooled estimate.
- Assessment
- Version 2 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This narrative review looked at how GLP-1 drugs affect cosmetic surgery, drawing on a targeted literature search from 2015 to 2026. It concludes that facial volume loss and loose skin more likely reflect fast weight loss than a direct drug effect, and that body-contouring results are mixed, with some studies finding similar complication rates and others more wound-healing problems. It reports no pooled numbers.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists
- Dose
- various
- Comparator
- not reported in abstract
- Primary outcome
- implications of GLP-1 RA use for aesthetic surgery (soft-tissue changes, wound healing, perioperative safety)
- Effect
- No pooled estimate; body contouring outcomes are heterogeneous, with some studies reporting comparable complication rates and others delayed wound healing and dehiscence
- 95% confidence interval
- not reported in abstract
- Follow-up
- Not stated
- Adverse events
- Body-contouring studies differ: some report comparable complication rates, others delayed wound healing, wound dehiscence, altered scarring or nutrition-related risks; perioperative aspiration risk needs assessment.
- Limitations
- A targeted narrative review, not a systematic one, of heterogeneous mostly observational and case-level literature; the authors say drug effects often cannot be separated from weight loss and that prospective studies are needed.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- aesthetic surgery patients using GLP-1 RAs
- Inclusion exclusion
- PubMed/MEDLINE literature January 2015 to August 2026 on GLP-1 RAs and aesthetic surgery
Study quality details
- Study design
- Narrative review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- none
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no pooled estimate or CI reported
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- The authors declared no conflicts of interest.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly relevant to aesthetic surgery because of the significant weight loss they provide in the treatment of type 2 diabetes mellitus and obesity. While these agents expand the pool of surgical candidates, they also raise new clinical questions related to rapid or substantial weight loss, including soft tissue volume loss, skin laxity, nutritional deficiencies, perioperative safety concerns, and the durability of aesthetic surgical outcomes. This contemporary narrative review evaluated the current implications of GLP-1 RAs in aesthetic plastic surgery practice. A targeted PubMed/MEDLINE search covering January 2015 through August 2026 was supplemented by manual reference screening. Retrospective cohorts, database analyses, prospective observational studies, systematic reviews, survey studies, case reports, and selected guidance or opinion articles were evaluated. Current literature indicates increasing demand for facial aesthetic, breast aesthetic, and body contouring procedures among patients using GLP-1 RAs. The facial volume loss and skin laxity popularly described as "Ozempic face" more plausibly reflect rapid or substantial weight loss than a proven drug-specific facial effect. Although the breast surgery literature remains limited, upper-pole volume loss, ptosis, reduced soft tissue support, and healing problems along high-tension closure lines are noteworthy. Outcomes in body contouring surgery are heterogeneous: While some studies report comparable complication rates, others emphasize delayed wound healing, wound dehiscence, altered scar behavior, or nutrition-related risks. Surgical timing, weight stabilization, nutritional balance, and individualized perioperative aspiration-risk assessment are key areas of evaluation. GLP-1 RA use should be considered neither an absolute advantage nor an automatic contraindication in aesthetic surgery. Direct pharmacologic effects often cannot be separated from the consequences of weight loss or baseline metabolic risk. Surgical decision-making should be individualized based on weight stability, metabolic optimization, nutritional status, history of bariatric surgery, psychological adaptation, and procedure-specific risks. Current evidence is promising but heterogeneous, and prospective studies are needed to clarify long-term aesthetic outcomes and procedure-specific risks.